MARKET

PBMWW

PBMWW

PSYENCE BIOMEDICAL LTD
NASDAQ
0.0210
-0.0011
-5.07%
Closed 15:45 05/15 EDT
OPEN
0.0204
PREV CLOSE
0.0221
HIGH
0.0224
LOW
0.0204
VOLUME
4.10K
TURNOVER
--
52 WEEK HIGH
0.0867
52 WEEK LOW
0.0110
MARKET CAP
--
P/E (TTM)
-0.0011
1D
5D
1M
3M
1Y
5Y
1D
PSYENCE BIOMED ANNOUNCES U.S. STRATEGIC ENGAGEMENT INITIATIVE FOCUSED ON GMP IBOGAINE RESEARCH AND MANUFACTURING
Reuters · 10h ago
Weekly Report: what happened at PBMWW last week (0504-0508)?
Weekly Report · 4d ago
Weekly Report: what happened at PBMWW last week (0427-0501)?
Weekly Report · 05/04 09:14
Weekly Report: what happened at PBMWW last week (0420-0424)?
Weekly Report · 04/27 09:15
Psyence BioMed begins Phase IIb dosing of NPX-5 in adjustment disorder trial
PUBT · 04/24 06:37
Psyence amends amalgamation agreement with GoldCoast Resource Corp
PUBT · 04/24 06:05
Psyence BioMed doses first patient in Phase IIb NPX-5 adjustment disorder trial
PUBT · 04/23 11:09
Weekly Report: what happened at PBMWW last week (0413-0417)?
Weekly Report · 04/20 09:14
More
About PBMWW
Psyence Biomedical Ltd is a multi-asset, vertically integrated biopharmaceutical company specializing in psychedelic-based therapeutics. The Company is focused on developing nature-derived (non-synthetic) psilocybin-based psychedelic medicine. It is dedicated to addressing unmet mental health needs, particularly in palliative care. Its ongoing Phase IIb psilocybin clinical trial in Australia focuses on adjustment disorder in patients diagnosed with cancer.

Webull offers Psyence Biomedical Ltd stock information, including NASDAQ: PBMWW real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PBMWW stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PBMWW stock methods without spending real money on the virtual paper trading platform.